Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 and Apatinib in Advanced NSCLC
NCT03083041Phase 2Completed
- Sponsor
- Hengrui
- Start
- Mar 2017
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hengrui. Primary endpoints: Incidence and Grade of Adverse Events and Serious Adverse Events at 61 months and Objective Response Rate at 61 months. Started Mar 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03083041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083041.